Form 4: Ocular Therapeutix CSO Sells Shares for Tax Obligations

Ocular Therapeutix Chief Strategy Officer Sanjay Nayak sold 1,878 shares of common stock at a weighted average price of $12.04 to cover tax withholding obligations from RSU vesting.

Summary

• Sanjay Nayak, Chief Strategy Officer of Ocular Therapeutix, Inc. (OCUL), reported a sale of common stock.
• The transaction involved the disposition of 1,878 shares of common stock on November 24, 2025.
• The shares were sold at a weighted average price of $12.04 per share, with prices ranging from $11.76 to $12.3412.
• This sale was executed pursuant to a durable automatic sale instruction (Rule 10b5-1(c) plan) adopted on February 21, 2024.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs) on November 22, 2025.
• The reporting person's beneficial ownership after this transaction is 277,860 shares of common stock.
• The sale does not represent a discretionary trade by Sanjay Nayak.

Sentiment

Score: 5

Explanation: The transaction is a non-discretionary sale to cover tax withholding obligations related to RSU vesting, executed under a pre-arranged 10b5-1 plan. This is a routine event and does not reflect a positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

N/A. This Form 4 reports a past, non-discretionary transaction and does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This transaction is a routine insider filing, common for executives to sell a portion of their vested equity awards to cover tax liabilities. Such 'sell-to-cover' transactions, especially when executed under a Rule 10b5-1 plan, are generally not indicative of management's sentiment about the company's future prospects but rather a standard financial planning practice.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes, executed under a pre-arranged plan. It does not signal a change in the company's fundamentals or management's confidence.

Key Dates

Recommendation

The filing details a non-discretionary sale of shares by a Chief Strategy Officer to cover tax obligations related to restricted stock unit vesting, executed under a pre-arranged 10b5-1 plan. This is a routine event and does not indicate a change in management's outlook or the company's fundamentals, thus a 'hold' recommendation is appropriate. Investors should focus on the company's operational performance and strategic developments rather than this standard insider transaction.

Keywords

OCULAR THERAPEUTIX, OCUL, Sanjay Nayak, Chief Strategy Officer, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, 10b5-1 Plan